Tower Research Capital (TRC)’s 2ndVote Life Neutral Plus ETF LYFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-10,520
Closed -$305K 6570
2022
Q4
$305K Buy
+10,520
New +$314K 0.01% 1003
2022
Q2
Sell
-42,712
Closed -$1.38M 6792
2022
Q1
$1.38M Buy
42,712
+18,906
+79% +$603K 0.01% 680
2021
Q4
$803K Buy
23,806
+2,655
+13% +$86.1K 0.01% 817
2021
Q3
$646K Buy
21,151
+7,038
+50% +$219K 0.02% 808
2021
Q2
$429K Sell
14,113
-6,243
-31% -$187K 0.01% 1315
2021
Q1
$580K Buy
20,356
+16,082
+376% +$439K 0.01% 1111
2020
Q4
$112K Buy
+4,274
New +$110K ﹤0.01% 2235

Other funds holding LYFE

Tower Research Capital (TRC)'s LYFE Position: Q1 2023 in Review

Tower Research Capital (TRC) sold out of 2ndVote Life Neutral Plus ETF (LYFE) in Q1 2023, closing a stake of 10,520 shares — an estimated $305K sold.

Tower Research Capital (TRC) first reported a position in LYFE in Q4 2020 and held it in 7 quarters. The position peaked at $1.38M in Q1 2022. 11 funds tracked by Wall St. Rank hold LYFE as of Q1 2023.

  • Tower Research Capital (TRC) reported no remaining 2ndVote Life Neutral Plus ETF position as of Q1 2023 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 10,520 2ndVote Life Neutral Plus ETF shares in Q1 2023, an estimated $305K.
  • Tower Research Capital (TRC) first reported a position in 2ndVote Life Neutral Plus ETF in Q4 2020 and held it in 7 quarters.
  • Tower Research Capital (TRC)'s 2ndVote Life Neutral Plus ETF position peaked at $1.38M in Q1 2022.
  • 11 funds tracked by Wall St. Rank held 2ndVote Life Neutral Plus ETF as of Q1 2023.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2023, filed 9 May 2023.